Tirzepatide 30MG

Tirzepatide 30 mg (brand names Mounjaro, Zepbound) is a once-weekly injectable medication primarily approved for treating type 2 diabetes and chronic weight management in adults, with additional use for obstructive sleep apnea (OSA) associated with obesity.

Benefits and Uses:

• Type 2 Diabetes Management: Tirzepatide lowers blood sugar by stimulating the pancreas to release insulin after meals and reducing glucagon secretion, which decreases new glucose production by the liver. These actions improve glycemic control and reduce HbA1c levels effectively. Tirzepatide’s glucose-dependent insulin release lowers the risk of hypoglycemia compared to some other diabetes drugs 1 2 4 5.

• Weight Loss and Obesity Management: By activating two gut hormone receptors (GLP-1 and GIP), tirzepatide reduces appetite, curbs food cravings, and slows gastric emptying. This leads to significant and sustained weight loss in people with obesity or overweight with related conditions such as hypertension or type 2 diabetes. Clinical trials demonstrated up to 21% body weight reduction with highest doses over weeks/months 1 3 6 7.

• Obstructive Sleep Apnea (OSA): Tirzepatide’s weight loss effect helps improve OSA symptoms by reducing fat deposits and inflammation that worsen airway obstruction 1.

Mechanism of Action:

• Tirzepatide is a dual receptor agonist targeting both GLP-1 and GIP receptors, enhancing meal-dependent insulin secretion and reducing glucagon release. It also slows digestion and acts on appetite centers in the brain to regulate hunger and satiety 1 3 4.

Dosage and Administration:

• Administered once weekly by subcutaneous injection.
• Dosage is typically titrated based on patient response, commonly between 5 mg and 15 mg per week; 30 mg is a higher dose possibly used in some protocols or formulations.
• Continued treatment is usually necessary to maintain glycemic and weight-loss benefits 1